SLC22A5 expression was shown to be upregulated in glioma cells, and its plasma membrane levels varied [95], with different SLC22A5 expression levels revealing a correlation between the rate of fatty acid oxidation (FAO) and the transporter level, as well as the carnitine transport. Here, SLC22A5 is linked to central nervous system cancer.